Journal of Multiple Sclerosis and Neuroimmunology

Search

Page Path

HOME
Search

Original Article

Ocrelizumab's Place in the Therapeutic Landscape at its 2019 Launch in France: Grégoire Mercier, David Pau, Guillaume Bourel, Manon Belhassen, Floriane Deygas, Clarisse Marchal, Sophie Larrieu, Alexandre Civet, Xavier Moisset; J Mult Scler Neuroimmunol. 2025;16(1):19-25. Published online June 30, 2025; DOI: https://doi.org/10.59578/jmsni.2025.16.1.19-25; PDF

Volume 16, No. 1

Journal of Multiple
Sclerosis and
Neuroimmunology

Print ISSN: 2733-8290
Online ISSN: 2951-2972

MOST VIEWED MOST CITED

7,560	Understanding MRI Features of Multiple Sclerosis: Based on the 2017 McDonald Criteria
4,086	Multiple Sclerosis in Korea: A Hospital-Based, Multicenter, Epidemiological Study
3,690	National Consensus Guidance for the Diagnosis and Management of Adult Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
3,566	Rituximab Treatment for Neuroimmunologic Disorders
2,918	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Review

Cited By 4	Multiple Sclerosis in Korea: A Hospital-Based, Multicenter, Epidemiological Study
Cited By 1	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Review
Cited By 1	National Consensus Guidance for the Diagnosis and Management of Adult Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Cited By 1	A Case of Post-Infective Myelin-Oligodendrocyte Glycoprotein Antibody-Associated Disease

Editorial Office: Department of Neurology, Chung-Ang University Hospital, Chung-Ang University College of Medicine 102, Heukseok-ro, Dongjak-gu, Seoul 06973, Korea
Tel: +82-2-6299-3153 E-mail: jmsni@koreams.org

Copyright © 2025 by Korean Society of Neuroimmunology.